Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5850_Библиотеки_им_академика_М_И_Перельмана
.pdf
Herbal Medicines fortheTreatment ofCOPD
https://t.me/medicina_free
177
Biological applicationsPlant extracts/secondary metabolites
• Lung cleansing
• Relieves breath illness
• Boosts immune systems
• Potential antioxidant activity
• Ease lung congestion
• Cleaning and purify lungs
Composition
racemosa, turmeric, vitamin C, Stinging Nettle, Lotus, gingever, pine bark
extract, and grape seed extract
Malabar nut, Glycyrrhiza glabra, Echinacea, curcumin, Arjuna, beetroot,
Stinging nettle, kateri, trikuta, punarnava, ginger and piperine
• Improves breathing
• Boost immunity
• Fights against lung damage
• Relied from mucus
Vasaka leaf, arjuna bark, Beetroot, stringing nettke root, kateri, trikatu,
• Stronger respiratory systems
• Lessens inammation
punarnava roots, echinacea roots, curcumin, and piperine
pollution
• Healthier breathing
• Protects the lungs against the harmful effects of
Stinging nettle extract, quercetin, Echinacea, lotus, ginger, licorice, Piper
nigrum, Inula Racemosa root extract, vitamin C, and grape seed extracts
• Helps detoxify the lungs
• Improves breathing by easing congestion
• Boosts respiratory health
• Puries and detox lungs
• Heals tissue damage due to the pollutions
• Provides relief from smoker’s cough
• Boosts lung immunity and strength
bark, oregano
congestion
• Potent bronchodilator
• Helpful in liquefying and relieving nasal and bronchial
• Its antimicrobial action combats infections caused by
Clerodendrumserratum, Aconitum ferox, Tinospora cordifolia, Zinziber
ofcinale, Piper nigrum, Piper longum, Datura mete, bambusaarundinacea,
Myristica gragrans, Elettaria cardamomum, Syzygiumaromaticum,
Gram-positive and Gram-negative bacteria
(COPD)
• Useful in chronic obstructive pulmonary disease
• Support overall lung and respiratory health
• Maintain healthy lung function
Cinnamomum zeylanicum
Inula helenium, Grindelia, Ceanothus americanus, Hawthorn and Schisandra
chinensis
• Promotes healthy lung functions
• Supports clear respiratory passages
• Supports healthy breathing capacity
• Naturally relieves
• Shortness of breath
• Relieves coughing
• Improves vital capacity
• Promotes expectoration
• Support overall lung and respiratory health
• Maintain healthy lung function
ofcinale, Tylophora asthmatica, Ganoderma lucidum and Vitamin C
Platycodon, ophiopogon, long pepper fruit, black cherry, cassia, elecampane,
mullein, licorice, and ginger
S.No. Name/brand
Table 3 List of commonly used herbal medicine and formulation available in market for COPD
1 Trurbasics/lung detox tablet Quercetin, Glycyrrhiza glabra, vitamin K2, Echinacea urpurea, Inula
2 Foresta organics/lung detox
tablet
detox tablet
3 Himalayan organics/lung
lung detox tablet
4 Pure nutrition (naturals)/
5 Nature sure/lungs pure tablet Vasika, guduchi, dhanyaka, kantakari, haridra, shunthi, bharangi, pipali, pine
lung complex
6 Shaleen/breath-easy Salanumsurrsttense, Adhatodavasica, Glycyrrhiza glabra, Ocimum sanctum,
7 Gaia herbs/mighty lungs Olea europaea, Ocimum sanctum, Mullein, Althaea ofcinalis, Plantain,
8 Redd remedies/lung care Adhatodavasica, Verbascum thapsus, Frillaria thunbergit, Zingiber
9 Organic India/breathe free Inula racemose, Ocimum sanctum, Terminalia belerica, Piper longum • Relieves asthma and other respiratory complications
10 Planetary herbals/mullein
178
https://t.me/medicina_free
S. R. Panda et al.
7 Secondary Metabolites Involved
intheInhibition ofCOPD
Herbal plants are the traditional and greatest extensive system of the drug for the cure of numerous human sicknesses
all over the world. Usually, the most successful sources of
potential natural products drugs have been derived from the
plants [124]. Plant-derived natural products are categorized
by huge chemical units with molecule structure and it shows
various biomedical applications [125]. Plant-derived natural
products such as Resveratrol (1), Curcumin (2), Emodin (3),
Linalool (4), Carvacrol (5), Quercetin (6), Forsythiaside (7),
Berberine (8), Baicalin (9), Chrysin (10), Casticin (11),
Oroxylin A (12), Asiatic acid (13), Lcariin (14),
Andrographolide (15), Betulin (16), Eucalyptol (17),
Epigallocatechin-3-gallate (18), p-Coumaric acid (19),
Salidroside (20), Silymarin (21), Tanshinone IIA (22),
Ursolic acid (23), and Phloretin (24) (Fig.3) showed promising activity, particularly in the inhibition of COPD [126].
Numerous reports revealed that many of the natural products
have employed efciently for the treatment of COPD in current studiesand it also exhibit efcacy on chronic lung
inammation related to COPD as summarized in Fig.3.
Resveratrol (1) (Fig.3) is a natural polyphenol antioxi-
dant agent and also called as 3,5,4′-trihydroxystilbene. It
was mainly identied from the roots of the white hellebore
Veratrum grandiorum and Polygonum japonicum [127]. It
has been used as traditional medicine such as asthma, antiseptic, wound healing for almost 2000 years [128]. It is
important to consider that resveratrol have been to found to
show anti-inammatory activity is displayed in COPD [129,
130]. Curcumin (2) is a chief component of Curcuma longa
(usually named as turmeric) and used as traditional medicine in the treatment of various inammatory disorders
(Fig.3). In addition to that, it shows different pharmacological including antioxidant, antimicrobial, anti-inammatory,
anticancer, and antidiabetic properties. Curcumin might be
an efcient COPD agent by preventing NF-κB signaling in
CS-induced COPD mice [131].The emodin (3) is known as
6-methyl-1,3,8-trihydroxyanthraquinone Fig. 3, an important compound and it was isolated from the Ventilago
madraspatana. It shows anti-inammatory activity via ele-
vation of Nrf-2 activation. Linalool (4) (Fig.3) is a fragrant
monoterpene alcohol, and it was isolated mainly from
Melissa ofcinalis and it displayed COPD property by preventing NF-κB initiation [132]. Carvacrol (5) Fig.3 is a terpenoid based compound which was identied from Zataria
multiora and which were used as traditional medicine such
as an antiseptic and anti-inammatory properties. Quercetin
(6) is avonoid-based polyphenol compound and it was
obtained from Polygonum aviculare medicinal plants.
Quercetin (Fig. 3) reduces chronic obstructive pulmonary
disease by Nrf2 activation [133]. The compound forsythia-
side (7, Fig. 3) contains 4-hydroxycinnamic acid moiety,
and it was isolated from Forsythia suspense herbal plant. It
exhibited COPD properties through inhibition of NF-κB
signaling pathway [134]. It is known that the alkaloid berberine (8) Fig. 3, from the Mexican traditional medicine
plant Argemone ochroleuca, in the treatment of asthma,
through NF-κB activation [135, 136]. A avonoid molecule
Baicalin (9) (Fig. 3) has been identied from the root of
Scutellaria baicalensis and it was exhibited promising
HDAC2 activity [137]. Chrysin (10) Fig. 3 was obtained
from medicinal plant of Passiora caerulea and showed bet-
ter anti-inammatory properties via potency of ERK and
p38 phosphorylation (Shen etal., 2015). Casticin (11) is avonoid compound Fig.3, isolated from the species of Vitex
such as Vitex rotun difolia and Vitex agnus-castus. It has
been found to have anti-inammatory lung diseases, chronic
obstructive pulmonary disease (COPD) [138]. The avonoid Oroxylin A (12) Fig.3 was found from medicinal plant
Scutellaria baicalensis Fig.3, attenuates CS-induced lung
inammation by Nrf2 activation [88]. Asiatic acid (13,
Fig.3), one of the bioactive natural products, isolated from
Centella asiatica, and it possesses inhibitory property
COPD through activation in lung tissue of MAPKs and
NF-kB.A new avonoid, icariin (14) Fig.3, has been isolated from Epimedium spp and considerably showed COPD
properties through the suppression of NF-kB activation. A
labdane diterpenoid Andrographolide (15, Fig. 3) was
mainly isolated from Andrographis paniculata herbal plant
and shown anti-inammatory properties through activation
of Nrf2 signaling pathway [139]. Betulin (16) Fig. 3 is a
rich, naturally occurring triterpene which was isolated from
the bark of birch trees. It exhibited COPD with decreasing
the amount of malondialdehyde (MDA) within the lung
[140]. Eucalyptol (17) Fig. 3 is a monoterpenoid bicyclic
ether and obtained from the plants of Eucalyptus globulus.
It has been played as a potential COPD agent for the action
of pulmonary inammation [141]. Epigallocatechin-3gallate (EGCG) (18) Fig.3 is a natural polyphenol isolated
from green leaf Camellia sinensis, and it showed promising
anti-inammatory activity through ameliorating oxidative
stress. The p-Coumaric acid (19) Fig. 3 is an important
hydroxycinnamic acid found in medicinal herbs Bambusae
Caulis in Taeniam and inhibits NF-κB activity and for treat-
ing pulmonary inammatory diseases. Salidroside (20)
Fig.3 is a glucoside of tyrosol was obtained from the medicinal plant Rhodiola rosea and it showed better COPD properties through MAPK/NF-κB mechanism [142]. An
important avonoid compound Silymarin (21), Fig.3, has
been isolated from the Silybum marianum, milk thistle, and
it exhibited COPD on adaptable MAPK activation mechanism [143]. Tanshinone IIA (22, Fig. 3) is the foremost
potential biomolecule which was isolated from the plant
root of Saviamiltiorrhiza. Tanshinone IIA induced COPD
Herbal Medicines fortheTreatment ofCOPD
https://t.me/medicina_free
179
Fig. 3 Some plant-derived natural products involved in the inhibition of COPD
180
https://t.me/medicina_free
S. R. Panda et al.
and down-regulation of CFTR, and it could be a potential
anti- inammatory drug for COPD.Ursolic acid (23), Fig.3,
is a tripterine-based terpenoid molecule, and it was obtained
from various medicinal plants such as Uncaria rhyncho-
phylla, Rosmarinus offıcinalis, and Eugenia jambolana.
Ursolic acid displays excellent COPD properties through it
mechanism of down-regulation of PERK and upregulation
of Nrf2 [144]. Phloretin (24) is a natural phenol dihydrochalcone Fig.3, and it has been identied from the apple
tree leaves Fortunella japonica and it was pretreatment dra-
matically suppressed the mucins secretion [145].
8 Conclusion
Herbal medicines potentially are used in the treatment of a
variety of diseases with reduced side effects and toxicities.
Several herbal drugs and formulations have shown marked
inhibition of acute and chronic illnesses including
COPD. Thus, our chapter in detail describes the various
herbal drugs and formulations with their detailed pre-clinical
studies.
Acknowledgment The authors thank and acknowledge the Department
of Pharmaceuticals, Ministry of chemical and fertilizers, Government
of India
Declaration of Competing Interest All the authors declare no conict of interest to publish the article.
References
1. Zagorevski DV, Loughmiller-Newman JA.The detection of nicotine in a Late Mayan period ask by gas chromatography and liquid chromatography mass spectrometry methods. Rapid Commun
Mass Spectrom. 2012;26(4):403–11.
2. Braun GV.Petrography as a technique for investigating Iroquoian
ceramic production and smoking rituals. J Archaeol Sci.
2012;39(1):1–10.
3. Kung H-C, Hoyert DL, Xu J, Murphy SL.Deaths: nal data for
2005. 2008.
4. May SM, Li JT.Burden of chronic obstructive pulmonary disease:
healthcare costs and beyond. In: Allergy and asthma proceedings.
East Providence: OceanSide Publications; 2015.
5. Barnes PJ, Burney PGJ, Silverman EK, Celli BR, Vestbo J,
Wedzicha JA, etal. Chronic obstructive pulmonary disease. Nat
Rev Dis Primers. 2015;1(1):15076.
6. Petty TL.The history of COPD.Int J Chron Obstruct Pulmon Dis.
2006;1(1):3–14.
7. Petrovska BB. Historical review of medicinal plants’ usage.
Pharmacogn Rev. 2012;6(11):1.
8. Chung K, Adcock I.Multifaceted mechanisms in COPD: inammation, immunity, and tissue repair and destruction. Eur Respir J.
2008;31(6):1334–56.
9. Milara J, Peiró T, Serrano A, Cortijo J.Epithelial to mesenchymal
transition is increased in patients with COPD and induced by cigarette smoke. Thorax. 2013;68(5):410–20.
10. Zhu B, Wang Y, Ming J, Chen W, Zhang L.Disease burden of
COPD in China: a systematic review. Int J Chron Obstruct Pulmon
Dis. 2018;13:1353.
11. Hou W, Hu S, Li C, Ma H, Wang Q, Meng G, etal. Cigarette
smoke induced lung barrier dysfunction, EMT, and tissue remodeling: a possible link between COPD and lung cancer. Biomed
Res Int. 2019;2019:2025636.
12. Rodgman A, Perfetti TA. The chemical components of tobacco
and tobacco smoke. Boca Raton: CRC Press; 2008.
13. John G, Kohse K, Orasche J, Reda A, Schnelle-Kreis J,
Zimmermann R, etal. The composition of cigarette smoke determines inammatory cell recruitment to the lung in COPD mouse
models. Clin Sci. 2014;126(3):207–21.
14. Caramori G, Adcock IM, Di Stefano A, Chung KF.Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon
Dis. 2014;9:397–412.
15. Boer WI, Alagappan VK, Sharma HS.Molecular mechanisms in
chronic obstructive pulmonary disease. Cell Biochem Biophys.
2007;1(47):131–47.
16. Kranenburg AR, Willems-Widyastuti A, Mooi WJ, Saxena PR,
Sterk PJ, de Boer WI, etal. Chronic obstructive pulmonary disease is associated with enhanced bronchial expression of FGF-1,
FGF-2, and FGFR-1. J Pathol. 2005;206(1):28–38.
17. Kranenburg AR, De Boer WI, Van Krieken JHJ, Mooi WJ,
Walters JE, Saxena PR, etal. Enhanced expression of broblast
growth factors and receptor FGFR-1 during vascular remodeling
in chronic obstructive pulmonary disease. Am J Respir Cell Mol
Biol. 2002;27(5):517–25.
18. Bonniaud P, Kolb M, Galt T, Robertson J, Robbins C, Stampi
M, et al. Smad3 null mice develop airspace enlargement and
are resistant to TGF-β-mediated pulmonary brosis. J Immunol.
2004;173(3):2099–108.
19. Fahy JV, Dickey BF.Airway mucus function and dysfunction. N
Engl J Med. 2010;363(23):2233–47.
20. Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M,
etal. Increased expression of transforming growth factor-β 1in
small airway epithelium from tobacco smokers and patients with
chronic obstructive pulmonary disease (COPD). Am J Respir Crit
Care Med. 2001;163(6):1476–83.
21. Tuder RM, Yoshida T, Arap W, Pasqualini R, Petrache I.State of
the art. Cellular and molecular mechanisms of alveolar destruction
in emphysema: an evolutionary perspective. Proc Am Thorac Soc.
2006;3(6):503–10.
22. Santos S, Peinado VI, Ramirez J, Morales-Blanhir J, Bastos R,
Roca J, etal. Enhanced expression of vascular endothelial growth
factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care
Med. 2003;167(9):1250–6.
23. Rahimi N, Dayanir V, Lashkari K. Receptor chimeras indicate
that the vascular endothelial growth factor receptor-1 (VEGFR-1)
modulates mitogenic activity of VEGFR-2in endothelial cells. J
Biol Chem. 2000;275(22):16986–92.
24. Kearney JB, Ambler CA, Monaco K-A, Johnson N, Rapoport RG,
Bautch VL.Vascular endothelial growth factor receptor Flt-1 negatively regulates developmental blood vessel formation by modulating endothelial cell division. Blood. 2002;99(7):2397–407.
25. Gaggar A, Jackson PL, Noerager BD, O’Reilly PJ, McQuaid DB,
Rowe SM, etal. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic
inammation. J Immunol. 2008;180(8):5662–9.
26. O'Reilly P, Jackson PL, Noerager B, Parker S, Dranseld M,
Gaggar A, etal. N-α-PGP and PGP, potential biomarkers and therapeutic targets for COPD.Respir Res. 2009;10:1–8.
27. Senior RM, Tegner H, Kuhn C, Ohlsson K, Starcher BC, Pierce
JA.The induction of pulmonary emphysema with human leukocyte elastase. Am Rev Respir Dis. 1977;126(3):469–75.
Herbal Medicines fortheTreatment ofCOPD
https://t.me/medicina_free
181
28. Duranton J, Bieth JG.Inhibition of proteinase 3 by α1-antitrypsin
invitro predicts very fast inhibition invivo. Am J Respir Cell Mol
Biol. 2003;29(1):57–61.
29. Barnes PJ, Shapiro SD, Pauwels R.Chronic obstructive pulmonary disease: molecular and cellularmechanisms. Eur Respir J.
2003;22(4):672–88.
30. Wang Z, Zheng T, Zhu Z, Homer RJ, Riese RJ, Chapman HA Jr,
etal. Interferon γ induction of pulmonary emphysema in the adult
murine lung. J Exp Med. 2000;192(11):1587–600.
31. Morris DG, Huang X, Kaminski N, Wang Y, Shapiro SD, Dolganov
G, etal. Loss of integrin αvβ6-mediated TGF-β activation causes
Mmp12-dependent emphysema. Nature. 2003;422(6928):169–73.
32. Imai K, Dalal SS, Chen ES, Downey R, Schulman LL, Ginsburg
M, etal. Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am J Respir Crit
Care Med. 2001;163(3):786–91.
33. Yu Q, Stamenkovic I.Cell surface-localized matrix metalloproteinase- 9 proteolytically activates TGF-β and promotes tumor
invasion and angiogenesis. Genes Dev. 2000;14(2):163–76.
34. Barnes PJ.Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):71–86.
35. Ito K, Watanabe S, Kharitonov S, Hanazawa T, Adcock I, Barnes
P. Histone deacetylase activity and gene expression in COPD
patients. Eur Respir J. 2001;18:316S.
36. Edwards MR, Bartlett NW, Clarke D, Birrell M, Belvisi M,
Johnston SL. Targeting the NF-κB pathway in asthma and
chronic obstructive pulmonary disease. Pharmacol Therap.
2009;121(1):1–13.
37. Caramori G, Romagnoli M, Casolari P, Bellettato C, Casoni G,
Boschetto P, etal. Nuclear localisation of p65in sputum macrophages but not in sputum neutrophils during COPD exacerbations.
Thorax. 2003;58(4):348–51.
38. Kennedy-Feitosa E, Cattani-Cavalieri I, Barroso MV, RomanaSouza B, Brito-Gitirana L, Valenca SS.Eucalyptol promotes lung
repair in mice following cigarette smoke-induced emphysema.
Phytomedicine. 2019;55:70–9.
39. Lee J-W, Park HA, Kwon O-K, Jang Y-G, Kim JY, Choi BK, etal.
Asiatic acid inhibits pulmonary inammation induced by cigarette
smoke. Int Immunopharmacol. 2016;39:208–17.
40. Hou J, Wang J, Meng J, Zhang X, Niu Y, Gao J, etal. Zanthoxylum
bungeanum seed oil attenuates LPS-Induced BEAS-2B cell activation and inammation by inhibiting the tlr4/Myd88/nf-κb
signaling pathway. Evid Based Complement Alternat Med.
2021;2021:1–13.
41. Sierocinski E, Holzinger F, Chenot J-F. Ivy leaf (Hedera helix)
for acute upper respiratory tract infections: an updated systematic
review. Eur J Clin Pharmacol. 2021;77:1113–22.
42. Guo R, Pittler M, Ernst E.Herbal medicines for the treatment of
COPD: a systematic review. Eur Respir J. 2006;28(2):330–8.
43. Kim J-Y, Shin D, Lee G, Kim J-M, Kim D, An Y-M, et al.
Standardized herbal formula PM014 inhibits radiation-induced
pulmonary inammation in mice. Sci Rep. 2017;7(1):45001.
44. Jasemi SV, Khazaei H, Momtaz S, Farzaei MH, Echeverría
J. Natural products in the treatment of pulmonary emphysema:
therapeutic effects and mechanisms of action. Phytomedicine.
2022;2022:153988.
45. Birrell MA, Eltom S. The role of the NLRP3 inammasome
in the pathogenesis of airway disease. Pharmacol Therap.
2011;130(3):364–70.
46. Zhang J, Xu Q, Sun W, Zhou X, Fu D, Mao L.New insights into
the role of NLRP3 inammasome in pathogenesis and treatment of chronic obstructive pulmonary disease. J Inamm Res.
2021;14:4155.
47. Swanson KV, Deng M, Ting JP-Y. The NLRP3 inammasome:
molecular activation and regulation to therapeutics. Nat Rev
Immunol. 2019;19(8):477–89.
48. Peng Z, Zhang W, Qiao J, He B. Melatonin attenuates airway
inammation via SIRT1 dependent inhibition of NLRP3 inammasome and IL-1β in rats with COPD. Int Immunopharmacol.
2018;62:23–8.
49. Mahalanobish S, Dutta S, Saha S, Sil PC.Melatonin induced suppression of ER stress and mitochondrial dysfunction inhibited
NLRP3 inammasome activation in COPD mice. Food Chem
Toxicol. 2020;144:111588.
50. Tian X, Xue Y, Xie G, Zhou Y, Xiao H, Ding F, et al.
(−)-Epicatechin ameliorates cigarette smoke-induced lung inammation via inhibiting ROS/NLRP3 inammasome pathway in rats
with COPD.Toxicol Appl Pharmacol. 2021;429:115674.
51. Zhang B, Wang B, Cao S, Wang Y, Wu D.Silybin attenuates LPSinduced lung injury in mice by inhibiting NF-κB signaling and
NLRP3 activation. Int J Mol Med. 2017;39(5):1111–8.
52. Tian Q, Xu M, He B. Histidine ameliorates elastase-and
lipopolysaccharide- induced lung inammation by inhibiting the
activation of the NLRP3 inammasome. Acta Biochim Biophys
Sin. 2021;53(8):1055–64.
53. Yang Y, Huang L, Tian C, Qian B.Magnesium isoglycyrrhizinate
inhibits airway inammation in rats with chronic obstructive pulmonary disease. BMC Pulm Med. 2021;21(1):1–11.
54. Tomani JCD, Kagisha V, Tchinda AT, Jansen O, Ledoux A,
Vanhamme L, etal. The inhibition of NLRP3 inammasome and
IL-6 production by hibiscus noldeae baker f. Derived constituents
provides a link to its anti-Inammatory therapeutic potentials.
Molecules. 2020;25(20):4693.
55. Moon P-D, Choi I-H, Kim H-M. Berberine inhibits the production of thymic stromal lymphopoietin by the blockade of
caspase- 1/NF-κB pathway in mast cells. Int Immunopharmacol.
2011;11(11):1954–9.
56. De Boer W.Cytokines and therapy in COPD: a promising combination? Chest. 2002;121(5):209S–18S.
57. Lee J-W, Ryu HW, Park S-Y, Park HA, Kwon O-K, Yuk HJ,
etal. Protective effects of neem (Azadirachta indica A.Juss.)
leaf extract against cigarette smoke-and lipopolysaccharideinduced pulmonary inammation. Int J Mol Med. 2017;40(6):
1932–40.
58. Yuan J, Li X, Fang N, Li P, Zhang Z, Lin M, et al. Perilla leaf
extract (PLE) attenuates COPD airway inammation via the
TLR4/Syk/PKC/NF-κB pathway in vivo and in vitro. Front
Pharmacol. 2022;12:763624.
59. Jian T, Ding X, Li J, Wu Y, Ren B, Li J, etal. Triterpene acids of
loquat leaf improve inammation in cigarette smoking induced
COPD by regulating AMPK/Nrf2 and NFκB pathways. Nutrients.
2020;12(3):657.
60. Jian T, Chen J, Ding X, Lv H, Li J, Wu Y, etal. Flavonoids isolated from loquat (Eriobotrya japonica) leaves inhibit oxidative
stress and inammation induced by cigarette smoke in COPD
mice: the role of TRPV1 signaling pathways. Food Funct.
2020;11(4):3516–26.
61. Lourenco JD, Neves LP, Olivo CR, Duran A, Almeida FM, Arantes
PM, etal. A treatment with a protease inhibitor recombinant from
the cattle tick (Rhipicephalus Boophilus microplus) ameliorates
emphysema in mice. PLoS One. 2014;9(6):e98216.
62. Rooney CP, Taggart C, Coakley R, McElvaney NG, O'Neill
SJ. Anti–proteinase 3 antibody activation of neutrophils can
be inhibited by α 1-antitrypsin. Am J Respir Cell Mol Biol.
2001;24(6):747–54.
63. Stolk J, Rossie W, Dijkman JH. Apocynin improves the efcacy
of secretory leukocyte protease inhibitor in experimental emphysema. Am J Respir Crit Care Med. 1994;150(6):1628–31.
64. Ma H, Zhou Z, Chen L, Wang L, Muge Q.Anemoside B4 prevents
chronic obstructive pulmonary disease through alleviating cigarette smoke-induced inammatory response and airway epithelial
hyperplasia. Phytomedicine. 2022;107:154431.
182
https://t.me/medicina_free
S. R. Panda et al.
65. Luo F, Shi J, Shi Q, Xu X, Xia Y, He X.Mitogen-activated protein kinases and hypoxic/ischemic nephropathy. Cell Physiol
Biochem. 2016;39(3):1051–67.
66. Barnes PJ.Novel signal transduction modulators for the treatment
of airway diseases. Pharmacol Therap. 2006;109(1-2):238–45.
67. Barnes PJ.Corticosteroid resistance in patients with asthma and
chronic obstructive pulmonary disease. J Allergy Clin Immunol.
2013;131(3):636–45.
68. Wang C, Zhou J, Wang J, Li S, Fukunaga A, Yodoi J, etal. Progress
in the mechanism and targeted drug therapy for COPD. Signal
Transduct Target Ther. 2020;5(1):248.
69. Manning BD, Toker A.AKT/PKB signaling: navigating the network. Cell. 2017;169(3):381–405.
70. Jiang H, Abel PW, Toews ML, Deng C, Casale TB, Xie Y, etal.
Phosphoinositide 3-kinase γ regulates airway smooth muscle
contraction by modulating calcium oscillations. J Pharmacol Exp
Ther. 2010;334(3):703–9.
71. Yao H, Rahman I. Current concepts on oxidative/carbonyl
stress, inammation and epigenetics in pathogenesis of chronic
obstructive pulmonary disease. Toxicol Appl Pharmacol.
2011;254(2):72–85.
72. Shi L, Yan J, Meng Y, Wang G, Du J, Feng C. Systematic
pharmacology- based strategy to explore the mechanism of
bufei huoxue capsule in the treatment of chronic obstructive
pulmonary disease. Evid Based Complement Alternat Med.
2022;2022:1129567.
73. Li D, Hu J, Wang T, Zhang X, Liu L, Wang H, etal. Silymarin
attenuates cigarette smoke extract-induced inammation via
simultaneous inhibition of autophagy and ERK/p38 MAPK pathway in human bronchial epithelial cells. Sci Rep. 2016;6(1):37751.
74. Luan G, Zhu Z, Wu K, Yin S.Theaavin-3,3′-digallate attenuates
cigarette smoke extract-induced pulmonary emphysema in mice
by suppressing necroptosis. Exp Ther Med. 2022;23(1):1–9.
75. Jeong J-S, Kim J-W, Kim J-H, Kim C-Y, Ko J-W, Kim
T-W.Protective effects of chestnut (Castanea crenata) inner shell
extract in macrophage-driven emphysematous lesion induced by
cigarette smoke condensate. Nutrients. 2023;15(2):253.
76. Zhou W, Dong M, Wu H, Li H-L, Ma R-y, Su W-W, etal. Common
mechanism of Citrus Grandis Exocarpium in treatment of chronic
obstructive pulmonary disease and lung cancer. Chin Herb Med.
2021;13(4):525–33.
77. Kao T-C, Wu C-H, Yen G-C. Glycyrrhizic acid and
18β-glycyrrhetinic acid recover glucocorticoid resistance via
PI3K-induced AP1, CRE and NFAT activation. Phytomedicine.
2013;20(3-4):295–302.
78. Pacini ES, Sanders-Silveira S, Godinho RO. The extracellular
cAMP-adenosine pathway in airway smooth muscle. J Pharmacol
Exp Ther. 2018;366(1):75–83.
79. Zuo H, Cattani-Cavalieri I, Musheshe N, Nikolaev VO, Schmidt
M.Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacol Ther. 2019;197:225–42.
80. Nabissi M, Marinelli O, Morelli MB, Nicotra G, Iannarelli R,
Amantini C, et al. Thyme extract increases mucociliary-beating
frequency in primary cell lines from chronic obstructive pulmonary disease patients. Biomed Pharmacother. 2018;105:1248–53.
81. Lee JW, Ryu HW, Lee SU, Kim MG, Kwon OK, Kim MO,
et al. Pistacia weinmannifolia ameliorates cigarette smoke and
lipopolysaccharide- induced pulmonary inammation by inhibiting interleukin-8 production and NF-κB activation. Int J Mol Med.
2019;44(3):949–59.
82. Tang G-H, Dong Z, Guo Y-Q, Cheng Z-B, Zhou C-J, Yin
S.Psiguajadials A–K.Unusual Psidium meroterpenoids as phosphodiesterase- 4 inhibitors from the leaves of Psidium guajava. Sci
Rep 2017;7(1):1-15.
83. Xiao C, Cheng S, Lin H, Weng Z, Peng P, Zeng D, et al.
Isoforskolin, an adenylyl cyclase activator, attenuates cigarette
smoke-induced COPD in rats. Phytomedicine. 2021;91:153701.
84. Faux SP, Tai T, Thorne D, Xu Y, Breheny D, Gaca M.The role of
oxidative stress in the biological responses of lung epithelial cells
to cigarette smoke. Biomarkers. 2009;14(sup1):90–6.
85. Li Y-j, Yu C-h, Li J-b, Wu X-y. Andrographolide antagonizes cigarette smoke extract-induced inammatory response and oxidative
stress in human alveolar epithelial A549 cells through induction of
microRNA-218. Exp Lung Res. 2013;39(10):463–71.
86. Liu X, Ma Y, Luo L, Zong D, Li H, Zeng Z, etal. Dihydroquercetin
suppresses cigarette smoke induced ferroptosis in the pathogenesis of chronic obstructive pulmonary disease by activating Nrf2mediated pathway. Phytomedicine. 2022;96:153894.
87. Ma B-n, Li X-j. Resveratrol extracted from Chinese herbal medicines: a novel therapeutic strategy for lung diseases. Chin Herb
Med. 2020;12(4):349–58.
88. Li J, Tong D, Liu J, Chen F, Shen Y.Oroxylin A attenuates cigarette smoke-induced lung inammation by activating Nrf2. Int
Immunopharmacol. 2016;40:524–9.
89. Barroso MV, Cattani-Cavalieri I, de Brito-Gitirana L, Fautrel A,
Lagente V, Schmidt M, etal. Propolis reversed cigarette smokeinduced emphysema through macrophage alternative activation
independent of Nrf2. Bioorg Med Chem. 2017;25(20):5557–68.
90. Lin L, Yin Y, Hou G, Han D, Kang J, Wang Q. Ursolic acid
attenuates cigarette smoke-induced emphysema in rats by regulating PERK and Nrf2 pathways. Pulm Pharmacol Therap.
2017;44:111–21.
91. Stojanoski NJ. Development of health culture. In: Veles and its
region from the past to the end of the 20th century, vol. 13. Veles:
Society of Science and Art; 1999. p.34.
92. Kelly K.The history of medicine. New York: Facts on File Inc;
2009.
93. Tucakov J.Healing with plants–phytotherapy. JBC. 1971;180:90.
94. Glesinger L.Medicine through centuries. JZZ. 1954;1:21–38.
95. Bojadzievski P. The health services in Bitola through the centuries. Bitola: Society of Science and Art; 1992. p.15–27.
96. Bazala V.The historical development of medicine in the Croatian
lands. Zagreb: Croation Publishing Bibliographic; 1943. p.9–20.
97. Tucakov J. Pharmacognosy. Beograd: Academic Books; 1948.
p.8–21.
98. Thorwald J.Power and knowledge of ancient physicians. Zagreb:
August Cesarec; 1991. p.10–255.
99. Benzie I, Wachtel-Galor S.Herbal medicine: an introduction to
its history, usage, regulation, current trends, and research needs.
Boca Raton: CRC Press; 2011. p.464.
100. Jancic R, Lakušic BJF. Zavod za botaniku. Belgrade: Botanika
Farmaceutika; 2002.
101. Mannino D, Watt G, Hole D, Gillis C, Hart C, McConnachie A,
et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(3):627–43.
102. Collins FS, Varmus H.A new initiative on precision medicine. N
Engl J Med. 2015;372(9):793–5.
103. Thomford NE, Senthebane DA, Rowe A, Munro D, Seele P,
Maroyi A, etal. Natural products for drug discovery in the 21st
century: innovations for novel drug discovery. Int J Mol Sci.
2018;19(6):1578.
104. Leung JM, Me O, Sadatsafavi M, Sin DD.Introduction to precision medicine in COPD.Eur Respir J. 2019;53(4):1802460.
105. Lyu YR, Lee S-W, Kim S-Y, Han H-B, Yang W-K, Kim S-H, etal.
Herbal medicines for the treatment of chronic obstructive airway
diseases (asthma or chronic obstructive pulmonary disease): a
prospective observational study. Evid Based Complement Alternat
Med. 2022;2022:3485757.
Herbal Medicines fortheTreatment ofCOPD
https://t.me/medicina_free
183
106. Sidhaye VK, Nishida K, Martinez F.Precision medicine in COPD:
where are we and where do we need to go? Eur Respir Rev.
2018;27(149):180022.
107. Iwakura M, Okura K, Kubota M, Sugawara K, Kawagoshi A,
Takahashi H, etal. Estimation of minimal clinically important difference for quadriceps and inspiratory muscle strength in older
outpatients with chronic obstructive pulmonary disease: a prospective cohort study. Phys Ther Res. 2021;24(1):35–42.
108. Clarke R, Lundy FT, McGarvey L.Herbal treatment in asthma
and COPD–current evidence. Int J Phytomed Phytother.
2015;1(1):1–7.
109. Deligiannidis KM, Freeman MP, Obstetrics RC.Complementary
and alternative medicine therapies for perinatal depression.
Gynaecology. 2014;28(1):85–95.
110. Guo S, Sun Z, Liu E, Feng J, Fu M, Li Y, et al. Effect of Bufei
granule on stable chronic obstructive pulmonary disease: a randomized, double blinded, placebo-controlled, and multicenter
clinical study. J Tradit Chin Med. 2014;34(4):437–44.
111. Zhang M, Xie Y, Yan R, Shan H, Tang J, Cai Y, etal. Curcumin
ameliorates alveolar epithelial injury in a rat model of chronic
obstructive pulmonary disease. Life Sci. 2016;164:1–8.
112. Karsch-Völk M, Barrett B, Kiefer D, Bauer R, ArdjomandWoelkart K, Linde K.Echinacea for preventing and treating the
common cold. Cochrane Database Syst Rev. 2014;2:CD000530.
113. Ma J, Liu X, Wei Y, Lu R, Xu K, Tian Y, etal. Effective component compatibility of Bufei Yishen formula III which regulates the
mucus hypersecretion of COPD rats via the miR-146a-5p/EGFR/
MEK/ERK pathway. BMC Pulm Med. 2022;2022:9423435.
114. Li J, Ma J, Tian Y, Zhao P, Liu X, Dong H, et al. Effectivecomponent compatibility of Bufei Yishen formula II inhibits mucus
hypersecretion of chronic obstructive pulmonary disease rats
by regulating EGFR/PI3K/mTOR signaling. J Ethnopharmacol.
2020;257:112796.
115. Zhao P, Liu X, Dong H, Tian Y, Feng S, Zhao D, et al. Bufei
Yishen formula restores Th17/Treg balance and attenuates chronic
obstructive pulmonary disease via activation of the adenosine 2a
receptor. Front Pharmacol. 2020;11:1212.
116. Li J, Yang L, Yao Q, Li Y, Tian Y, Li S, etal. Effects and mechanism of Bufei Yishen formula in a rat chronic obstructive pulmonary disease model. Evid Based Complement Alternat Med.
2014;2014:381976.
117. Liu S, Chen J, Zuo J, Lai J, Wu L, Guo XJB, etal. Comparative
effectiveness of six Chinese herb formulas for acute exacerbation
of chronic obstructive pulmonary disease: a systematic review
and network meta-analysis. BMC Complement Altern Med.
2019;19:1–14.
118. Wu Y, Liu T, Liu S.Impact of Xiaoqinglong decoction on lung
function and serum cytokines in patients with acute exacerbation of chronic obstructive pulmonary disease. Med Innov China.
2015;12:109–11.
119. Cao D.Effects of Xiaoqiongtang decoction on airway inammation and airway remodeling in patients with COPD.J West China.
2009;21(4):575–7.
120. Jing X, Li X, Liu J.Effect of modied Qianjin Weijing decoction
on nuclear factor-Kb of chronic obstructive pulmonary disease in
acute stage. J Shandong Univ TCM. 2007;14(5):271–4.
121. Zhang W, Zhang X, Shao Y. Changes in the level of cytokine in
rats with chronic obstructive pulmonary disease of phlegm heat
cumber lung type after treatment of Maxing Shigan decoction.
Chin J Tissue Eng Res. 2006:167–70.
122. Cai M, Chen H, Wang X-D, Zhang H-Y.Clinical observation of
bushen naqi huoxue granules in treating patients with chronic
obstructive lung disease. JCIM J. 2005;3(6):483–5.
123. Soraoka H, Oniki K, Matsuda K, Ono T, Taharazako K, Uchiyashiki
Y, etal. The effect of Yokukansan, a traditional herbal preparation
used for the behavioral and psychological symptoms of dementia,
on the drug–metabolizing enzyme activities in healthy male volunteers. Biol Pharm Bull. 2016;39(9):1468–74.
124. Raee Z, Nejatian M, Daeihamed M, Jafari SM.Application of
curcumin-loaded nanocarriers for food, drug and cosmetic purposes. Trends Food Sci Technol. 2019;88:445–58.
125. Scotti L, Ishiki H, Júnior F, Cruz R, Tavares J, Diniz M, etal.
Flavonoids as multi-target compounds in drug discovery. Curr
Pharm Des. 2017;14(4):333–41.
126. Bolognesi ML, Cavalli AJC.Multitarget drug discovery and polypharmacology. Hoboken: Wiley; 2016. p.1190–2.
127. Gambini J, Inglés M, Olaso G, Lopez-Grueso R, Bonet-Costa
V, Gimeno-Mallench L, et al. Properties of resveratrol: invitro
and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxidative Med Cell
Longev. 2015;2015:837042.
128. Pangeni R, Sahni JK, Ali J, Sharma S, Baboota S.Resveratrol:
review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Deliv. 2014;11(8):1285–98.
129. Wang X-L, Li T, Li J-H, Miao S-Y, Xiao X-Z.The effects of resveratrol on inammation and oxidative stress in a rat model of
chronic obstructive pulmonary disease. J Med. 2017;22(9):1529.
130. Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P,
Anand P, Pandey MK, etal. Resveratrol, a multitargeted agent,
can enhance antitumor activity of gemcitabine in vitro and in
orthotopic mouse model of human pancreatic cancer. Int J Cancer.
2010;127(2):257–68.
131. Yuan J, Liu R, Ma Y, Zhang Z, Xie Z.Curcumin attenuates airway inammation and airway remolding by inhibiting NF-κB
signaling and COX-2 in cigarette smoke-induced COPD mice.
Inammation. 2018;41:1804–14.
132. Ma J, Xu H, Wu J, Qu C, Sun F, Xu S.Linalool inhibits cigarette
smoke-induced lung inammation by inhibiting NF-κB activation.
Int Immunopharmacol. 2015;29(2):708–13.
133. Mitani A, Azam A, Vuppusetty C, Ito K, Mercado N, Barnes
PJ. Quercetin restores corticosteroid sensitivity in cells from
patients with chronic obstructive pulmonary disease. Exp Lung
Res. 2017;43(9-10):417–25.
134. Cheng L, Li F, Ma R, Hu X. Forsythiaside inhibits cigarette
smoke-induced lung inammation by activation of Nrf2 and inhibition of NF-κB.Int Immunopharmacol. 2015;28(1):494–9.
135. Lin K, Liu S, Shen Y, Li Q. Berberine attenuates cigarette
smoke- induced acute lung inammation. Inammation.
2013;36:1079–86.
136. Xu D, Wan C, Wang T, Tian P, Li D, Wu Y, etal. Berberine attenuates cigarette smoke-induced airway inammation and mucus
hypersecretion in mice. Int J Clin Exp Med. 2015;8(6):8641.
137. Park K, Lee JS, Choi JS, Nam YJ, Han JH, Byun HD, et al.
Identication and characterization of baicalin as a phosphodiesterase 4 inhibitor. Phytother Res. 2016;30(1):144–51.
138. Lee H, Jung K-H, Lee H, Park S, Choi W, Bae H. Casticin, an
active compound isolated from Vitex Fructus, ameliorates the
cigarette smoke-induced acute lung inammatory response in a
murine model. Int Immunopharmacol. 2015;28(2):1097–101.
139. Liao W, Tan WD, Wong WF. Andrographolide restores steroid sensitivity to block lipopolysaccharide/IFN-γ-induced
IL-27 and airway hyperresponsiveness in mice. J Immunol.
2016;196(11):4706–12.
140. Chunhua M, Long H, Zhu W, Liu Z, Jie R, Zhang Y, etal. Betulin
inhibited cigarette smoke-induced COPD in mice. Biomed
Pharmacother. 2017;85:679–86.
184
https://t.me/medicina_free
S. R. Panda et al.
141. Yu N, Sun Y-T, Su X-M, He M, Dai B, Kang J.Treatment with eucalyptol mitigates cigarette smoke-induced lung injury through suppressing ICAM-1 gene expression. Biosci Rep. 2018;38(4):1636.
142. Luo F, Liu J, Yan T, Miao M.Salidroside alleviates cigarette smokeinduced COPD in mice. Pharmacotherapy. 2017;86:155–61.
143. Daryanto S, Wang L, Jacinthe P-A.Impacts of no-tillage management on nitrate loss from corn, soybean and wheat cultivation: a
meta-analysis. Sci Rep. 2017;7(1):12117.
144. Liu W, Tan X, Shu L, Sun H, Song J, Jin P, etal. Ursolic acid inhibits cigarette smoke extract-induced human bronchial epithelial
cell injury and prevents development of lung cancer. Molecules.
2012;17(8):9104–15.
145. Wang H, Yang T, Wang T, Hao N, Shen Y, Wu Y, etal. Phloretin
attenuates mucus hypersecretion and airway inammation induced
by cigarette smoke. Int Immunopharmacol. 2018;55:112–9.
Herbal Medicines fortheTreatment
https://t.me/medicina_free
ofLiver Cirrhosis
TanmoyBanerjee, ShuvamSar, SaptapadiSaha,
ArunBaidya, ArnabSarkar, SanmoyKarmakar,
AmitKumarHalder, andNilanjanGhosh
Abstract
Liver cirrhosis is a disastrous terminal consequence of
different types of chronic liver diseases (CLDs), with
brosis serving as an initial stage of cirrhosis. Obesity,
hyperlipidaemia, and type 2 diabetes mellitus (T2DM)
signicantly raise the possibility of liver cirrhosis and its
associated consequences. Non-alcoholic steatohepatitis
(NASH), a physiological condition with a 20% progression rate to cirrhosis, is brought on by the excessive lipid
accumulation in non-alcoholic fatty liver disease
(NAFLD) that results in inammation and destroys the
normal hepatocytes. Cirrhosis and brosis of the liver are
complex diseases that include different inammatory
cytokines and genetic, oxidative, and endoplasmic reticulum (ER) stress factors. The prevalence of cirrhosis in
humans is increasing, which is of particular concern to
medical specialists. However, there are not many efcient
treatments readily accessible right now. Numerous molecules from phytochemical classes, including alkaloid, avonoid, glycoside, polyphenol, tannin, and terpenoid,
have shown promising results in treating several CLDs
progressing to cirrhosis. These compounds inuence
hepatic lipid metabolism and de novo lipogenesis (DNL)
through various molecular signalling pathways. In this
chapter, several natural compounds implicated in reversing liver cirrhosis development via numerous molecular
pathways have been briey described. In-depth descriptions of various phytochemicals acting onmultiple cell
lines, and well-established animal models of cirrhosisare
discussed in detail. Therefore, with adequate scientic
evidence, this chapter conveys the role of herbal medicines in altering the progression of liver cirrhosis.
Keywords
Liver cirrhosis · Herbal compounds · Chronic liver
diseases · Lipid metabolism · Molecular targets
Abbreviations
ACC Acetyl-CoA carboxylase
ALT Alanine aminotransferase
AST Aspartate aminotransferase
CCl4 Carbon tetrachloride
ChREBP Carbohydrate-responsive element-binding
protein
HDL-C High-density lipoprotein cholesterol
IL-1β Interleukin-1β
IL-6 Interleukin 6
LDL-C Low-density lipoprotein cholesterol
MDA Malondialdehyde
mRNA Messenger ribonucleic acid
NLRP3 NLR family pyrin domain containing 3
Nrf2 Factor-erythroid 2 related factor 2
p53 Tumour protein P53
PPAR-α Peroxisome proliferator-activated receptor α
PPAR-γ Peroxisome proliferator-activated receptor γ
PPAR-δ Peroxisome proliferator-activated receptor δ
SOD Superoxide dismutase
SREBP-1c Sterol regulatory element-binding protein-1c
TC Total cholesterol
T. Banerjee · S. Sar · S. Saha · A. Baidya · A. Sarkar · S. Karmakar
· N. Ghosh (*)
Department of Pharmaceutical Technology, Jadavpur University,
Kolkata, West Bengal, India
e-mail: nilanjanghosh.phamacy@jadavpuruniversity.in
A. K. Halder
Dr. B.C.Roy College of Pharmacy & Allied Health Sciences,
Durgapur, India
© The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2023
A. K. Dhara, S. C. Mandal (eds.), Role of Herbal Medicines, https://doi.org/10.1007/978-981-99-7703-1_10
1 Introduction
Liver cirrhosis is a major cause of mortality and a serious
public health concern globally. In 2016, liver cirrhosis was
responsible for 2.2% of fatalities and 1.5% of patient disabil-
185
186
https://t.me/medicina_free
T. Banerjee et al.
Fig. 1 Progression of liver cirrhosis from NAFLD and NASH to hepatocellular carcinoma
ity globally, making it the eleventh major death-related factor [1]. The majority of severe liver illnesses are characterized
by extracellular matrix protein buildup, particularly collagen, resulting in hepatic brosis. Liver cirrhosis is the outcome of progressive liver brosis [2]. The brosis and
regenerative nodule development can describe liver cirrhosis
because chronic damage disrupts the hepatic lobular structure. Viral infections, poisons, genetic disorders, and autoim-
drugs used to manage liver illnesses are now derived from
natural sources. Furthermore, some data states that the bioactive chemicals found in botanicals can operate as hepatoprotective agents [8]. Hence, this chapter aims to conduct an
in-depth evaluation of the bioactive chemicals from plant
species that inhibit liver cirrhosis and associated liver ailments by regulating multiple gene and protein expressions
by several molecular signalling pathways.
mune processes are all examples of assaults that may harm
healthy hepatocytes. In prolonged damage conditions, most
hepatocyte brosis results in liver impairment [3]. Non-
2 Pathophysiology
alcoholic fatty liver disease (NAFLD) can be described by an
accumulation of lipids in the liver that cannot be attributed to
alcohol intake in individuals [4]. Non-alcoholic steatohepatitis (NASH) is characterized by a higher degree of brosis
advancement from NAFLD [5]. NASH includes a spectrum
of clinical conditions that may progress from steatosis to cirrhosis and ultimately cause liver cancer (Fig.1) [6].
Synthetic medications traditionally used to cure liver disorders have proven fatal in several instances. Herbal medicines play a crucial role in a wide variety of hepatic disorders
for having less or negligible side effects and long-term therapeutic effects, which makes them signicantly popular [7].
About 65% of sufferers in Europe and the USA rely on
herbal medicaments for the treatment of liver ailments. The
prompting move towards natural compounds or their derivatives could be benecial in retarding liver cirrhosis. Most
The complicated processes that may be responsible for the
development of NAFLD in patients with type 2 diabetic mellitus (T2DM) have mostly been the focus of research [9]. It
has been established that fatty liver disease, obesity, and insulin resistance (IR) play a signicant role as co-factors in
developing liver damage [10]. Absorption of free fatty acids
(FFAs) and de novo lipogenesis (DNL) in the liver are the two
primary contributors to NAFLD, which is the outcome of an
intracellular buildup of triglyceride (TG). The hepatic damage comprises cellular destruction and inammation. These
illnesses result from a rise in mitochondrial oxidative stress
on TG, forming free radicals and peroxisomes as a downstream consequence [11]. DNL regulates the balance between
lipid synthesis and its breakdown, and the imbalance between
these two is what causes hepatic lipid accumulation. DNL is
Соседние файлы в папке Библиотека им академика М.И. Перельмана